Potassium deficiency decreases the capacity for urea synthesis and markedly increases ammonia in rats

Author(s):  
Anne Catrine Daugaard Mikkelsen ◽  
Karen Louise Thomsen ◽  
Hendrik Vilstrup ◽  
Luise Aamann ◽  
Helen Jones ◽  
...  

Background and Aims: Potassium deficiency decreases gene expression, protein synthesis, and growth. The urea cycle maintains body nitrogen homeostasis including removal of toxic ammonia. Hyperammonemia is an obligatory trait of liver failure, increasing the risk for hepatic encephalopathy, and hypokalemia is reported to increase ammonia. We aimed to clarify the effects of experimental hypokalemia on the in vivo capacity of the urea cycle, on the genes of the enzymes involved, and on ammonia concentrations. Method: Female Wistar rats were fed a potassium free diet for 13 days. Half of the rats were then potassium repleted. Both groups were compared to pair- and free-fed controls. The following were measured: in vivo capacity of urea-nitrogen synthesis (CUNS); gene expression (mRNA) of urea cycle enzymes; plasma potassium, sodium, and ammonia; intracellular potassium, sodium, and magnesium in liver, kidney, and muscle tissues, and liver sodium/potassium pumps. Liver histology was assessed. Results: The diet induced hypokalemia of 1.9±0.4 mmol/L. Compared to pair-fed controls, the in vivo CUNS was reduced by 34% (p<0.01), gene expression of argininosuccinate synthetase 1 (ASS1) was decreased by 33% (p<0.05), and plasma ammonia concentrations were eightfold elevated (p<0.001). Kidney and muscle tissue potassium contents were markedly decreased, but unchanged in liver tissue. Protein expressions of liver sodium/potassium pumps were unchanged. Repletion of potassium reverted all the changes. Conclusion: Hypokalemia decreased the capacity for urea synthesis via gene effects. The intervention led to marked hyperammonemia, quantitatively explainable by the compromised urea cycle. Our findings motivate clinical studies of patients with liver disease.

2017 ◽  
Vol 115 (2) ◽  
pp. 391-396 ◽  
Author(s):  
Leandro R. Soria ◽  
Gabriella Allegri ◽  
Dominique Melck ◽  
Nunzia Pastore ◽  
Patrizia Annunziata ◽  
...  

Ammonia is a potent neurotoxin that is detoxified mainly by the urea cycle in the liver. Hyperammonemia is a common complication of a wide variety of both inherited and acquired liver diseases. If not treated early and thoroughly, it results in encephalopathy and death. Here, we found that hepatic autophagy is critically involved in systemic ammonia homeostasis by providing key urea-cycle intermediates and ATP. Hepatic autophagy is triggered in vivo by hyperammonemia through an α-ketoglutarate–dependent inhibition of the mammalian target of rapamycin complex 1, and deficiency of autophagy impairs ammonia detoxification. In contrast, autophagy enhancement by means of hepatic gene transfer of the master regulator of autophagy transcription factor EB or treatments with the autophagy enhancers rapamycin and Tat-Beclin-1 increased ureagenesis and protected against hyperammonemia in a variety of acute and chronic hyperammonemia animal models, including acute liver failure and ornithine transcarbamylase deficiency, the most frequent urea-cycle disorder. In conclusion, hepatic autophagy is an important mechanism for ammonia detoxification because of its support of urea synthesis, and its enhancement has potential for therapy of both primary and secondary causes of hyperammonemia.


Author(s):  
Robert W L Siebers ◽  
Carl D Burgess ◽  
Amber Flatt ◽  
Richard Beasley ◽  
Julian Crane

Administration of the beta2 adrenergic agonists fenoterol, salbutamol and terbutaline to volunteers significantly reduced plasma potassium concentration in a double-blind crossover study. There was no consistent effect of the three active compounds on erythrocyte sodium concentration. Storage of whole blood at 4°C increased erythrocyte sodium concentration by 33% after 2 h; this could explain the differences between this and another study of the effects of beta2 adrenergic agonists on erythrocyte sodium concentration. We conclude that the human erythrocyte is unsuitable as an indirect in vivo model to demonstrate stimulation of cellular sodium potassium transport mediated by beta2 adrenergic agonists.


1998 ◽  
Vol 275 (1) ◽  
pp. E79-E86 ◽  
Author(s):  
Thorbjørn Grøfte ◽  
Dorthe Svenstrup Jensen ◽  
Henning Grønbæk ◽  
Troels Wolthers ◽  
Søren Astrup Jensen ◽  
...  

Growth hormone (GH) reduces the catabolic side effects of steroid treatment due to its effects on tissue protein synthesis/degradation. Little attention is focused on hepatic amino acid degradation and urea synthesis. Five groups of rats were given 1) placebo, 2) prednisolone, 3) placebo, pair fed to the steroid group, 4) GH, and 5) prednisolone and GH. After 7 days, the in vivo capacity of urea N synthesis (CUNS) was determined by saturating alanine infusion, in parallel with measurements of liver mRNA levels of urea cycle enzymes, N contents of organs, N balance, and hormones. Prednisolone increased CUNS (μmol ⋅ min−1 ⋅ 100 g−1, mean ± SE) from 9.1 ± 1.0 (pair-fed controls) to 13.2 ± 0.8 ( P < 0.05), decreased basal blood α-amino N concentration from 4.2 ± 0.5 to 3.1 ± 0.3 mmol/l ( P < 0.05), increased mRNA levels of the rate- and flux-limiting urea cycle enzymes by 20 and 65%, respectively ( P < 0.05), and decreased muscle N contents and N balance. In contrast, GH decreased CUNS from 6.1 ± 0.9 (free-fed controls) to 4.2 ± 0.5 ( P < 0.05), decreased basal blood α-amino N concentration from 3.8 ± 0.3 to 3.2 ± 0.2, decreased mRNA levels of the rate- and flux-limiting urea cycle enzymes to 60 and 40%, respectively ( P < 0.05), and increased organ N contents and N balance. Coadministration of GH abolished all steroid effects. We found that prednisolone increases the ability of amino N conversion into urea N and urea cycle gene expression. GH had the opposite effects and counteracted the N-wasting side effects of prednisolone.


2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Erika Calvano Küchler ◽  
Rafaela Mariana de Lara ◽  
Marjorie Ayumi Omori ◽  
Guido Marañón-Vásquez ◽  
Flares Baratto-Filho ◽  
...  

Abstract Background Estrogen is a well-known and important hormone involved in skeletal homeostasis, which regulates genes involved in bone biology. Some studies support that estrogen is important for craniofacial growth and development. Therefore this in vivo animal study aimed to investigate, whether and in which way low estrogen levels in the prepubertal period affect craniofacial development in the postpubertal stage and to quantify the gene expression of RANK, RANKL and OPG in cranial growth sites in ovariectomized estrogen-deficient rats during puberty. Methods Control (sham-operated, n = 18) and ovariectomy (OVX, n = 18) surgeries were performed on 21-days-old female Wistar rats. Animals euthanized at an age of 45 days (pubertal stage) were used for gene expression analyses (n = 6 per group) and immunohistochemistry of RANK, RANKL and OPG. Animals euthanized at 63 days of age (post-pubertal stage) were used for craniofacial two-dimensional and three-dimensional craniofacial measurements using μCT imaging (n = 12 per group). Results In the μCT analysis of the mandible and maxilla many statistically significant differences between sham-operated and OVX groups were observed, such as increased maxillary and mandibular bone length in OVX animals (p < 0.05). Condylar volume was also significantly different between groups (p < 0.05). The sham-operated group showed a higher level of RANK expression in the midpalatal suture (p = 0.036) and the RANKL:OPG ratio levels were higher in the OVX group (p = 0.015). Conclusions Our results suggest that estrogen deficiency during the prepubertal period is associated with alterations in the maxillary and mandibular bone length and condylar growth.


2008 ◽  
Vol 46 (01) ◽  
Author(s):  
F Moriconi ◽  
H Christiansen ◽  
H Christiansen ◽  
N Sheikh ◽  
J Dudas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document